@article{f1bc4e3cb29a453e8d7d6b0d0d1b671e,
title = "World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult - A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation",
abstract = "Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its pathophysiology remains poorly understood and its treatment remains undefined. Pulmonary hypertension in the context of left heart disease is a marker of worse prognosis and disease severity, but whether its primary treatment is beneficial or harmful is unknown. An important step to the future study of this important clinical problem will be to standardize definitions across disciplines to facilitate an evidence base that is interpretable and applicable to clinical practice. In this current statement, we provide an extensive review and interpretation of the current available literature to guide current practice and future investigation. At the request of the Pulmonary Hypertension (PH) Council of the International Society for Heart and Lung Transplantation (ISHLT), a writing group was assembled and tasked to put forth this document as described above. The review process was facilitated through the peer review process of the Journal of Heart and Lung Transplantation and ultimately endorsed by the leadership of the ISHLT PH Council.",
keywords = "heart failure, heart transplant, left heart disease, left ventricular assist device, pulmonary hypertension, right heart failure",
author = "Fang, {James C.} and Teresa Demarco and Givertz, {Michael M.} and Borlaug, {Barry A.} and Lewis, {Gregory D.} and Rame, {J. Eduardo} and Mardi Gomberg-Maitland and Srinivas Murali and Frantz, {Robert P.} and Dana McGlothlin and Horn, {Evelyn M.} and Benza, {Raymond L.}",
note = "Funding Information: No primary funding sources supported this project. Gregory D. Lewis, MD, received support from National Heart, Lung and Blood Institute , National Institutes of Health Grants K23-HL091106 and U01-HL084877 . Funding Information: The following financial relationships are disclosed: Teresa DeMarco, MD, Actelion (speaker's bureau), Gilead (speaker's bureau and endpoints committee), and United Therapeutics (speaker's bureau and research grant). Michael M. Givertz, MD, Cardioxyl (clinical advisory board). Gregory D. Lewis, MD, Pfizer (research grant). Mardi Gomberg, MD, Actelion (consultant, research support), Gilead (consultant, research support), Pfizer (consultant, research support), United Therapeutics (consultant, research support), Novartis (research support), Lilly/Icos, Biomarin (consultant), and Biomarin (consultant). Raymond L. Benza, MD, United Therapeutics (research support, honorarium), Gilead (research support), Bayer (research support, honorarium), GeNo (research support), Ikaria (research support), Actelion (honorarium), Robert Frantz, MD, Pfizer (consulting), United Therapeutics (research support), Dana McGlothlin, MD, Actelion (research support, honoraria), United Therapeutics (research support, honoraria), and Gilead (honoraria). None of the other authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.",
year = "2012",
month = sep,
doi = "10.1016/j.healun.2012.06.002",
language = "English (US)",
volume = "31",
pages = "913--933",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "9",
}